Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berobenatide in knee osteoarthritis and overweight/obesity
NCT07919678Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Oct 2026
- Primary completion
- Aug 2028
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of berobenatide in knee osteoarthritis (OA) and obesity (4 arms), sponsored by Pfizer. Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis Index Pain Subscale score at 52 weeks. Started Oct 2026; status: recruiting.
02
Drugs
berobenatide
03
Conditions
knee osteoarthritis (OA)obesity
Beyond the preview
Go deeper on NCT07919678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07919678.